Ticagrelor is a platelet aggregation inhibitor. It works by slowing or stopping platelets from sticking to blood vessel walls or injured tissues. A recent publication in the BMJ journal Heart has tried to find out the effect of ticagrelor and aspirin co-administration in graft patency. Graft patency and completeness of revascularization are major determinants of long-term outcome following coronary artery bypass graft (CABG) procedures.
Ticagrelor was shown to reduce mortality in patients who underwent coronary artery bypass grafting (CABG), but its effect on graft patency is unknown. Results of a randomised, double-blind, placebo-controlled trial to assess the effect of ticagrelor and aspirin co-administration in the patency of graft post CABG. Method This prospective, randomised, double-blind, placebo-controlled trial, compared ticagrelor 90 mg twice daily versus placebo for 3 months…
